<DOC>
	<DOCNO>NCT01973413</DOCNO>
	<brief_summary>The primary goal test function Diabetes Assistant ( DiAs ) enhance control-to-range ( CTR ) controller closely monitor diabetes camp setting . The camp set allow u obtain pilot efficacy data .</brief_summary>
	<brief_title>Diabetes Assistant ( DiAs ) Control-to-Range ( CTR ) Nocturnal Closed-Loop Camp Study</brief_title>
	<detailed_description>The first phase study test feasibility initialize DiAs CTR system clinical research center . We test procedure occur camp study , consent subject , obtain morning glucose reading , initialize sensor early afternoon , light activity evening , bedtime snack , initialize closed-loop system within 30 minute go bed . We also test system performs use calibration blood glucose monitoring do camp . In inpatient study mimic camp activity subject 20-30 minute aerobic activity afternoon evening dinner . The data inpatient study review Data Safety Monitoring Board ( DSMB ) proceed Phase 2 summer camp study . The second phase proposal `` in-camp '' study . The health care provider conduct inpatient study conduct camp study . They monitor camper closed-loop control real-time . Participants randomize either closed-loop ( experimental ) sensor-augmented therapy ( control ) first night cross every night therapy course 5- 6-day camp session ( i.e . DiAs CTR every night ) . Those assigned DiAs CTR control remotely monitor throughout night . Those assigned control group remote monitor overnight , wear Dexcom G4Platinum sensor active low high sensor glucose alarm . Initial study do camp old child camp staff age 15-35 year age , least 5 subject 15 18 year old . If study safe ( DSMB review ) additional camp include child 10-14 year old .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<criteria>1 . Clinical diagnosis type 1 diabetes use daily insulin therapy least one year Medtronic , Animas Tandem insulin infusion pump least 3 month 2 . The diagnosis type 1 diabetes base investigator 's judgment ; C peptide level antibody determination require . 3 . Age 10.0 35 year 4 . Willingness use SureT Contact Detach infusion set camp 1 . Diabetic ketoacidosis past month 2 . Hypoglycemic seizure loss consciousness past 3 month 3 . History seizure disorder ( except hypoglycemic seizure ) 4 . Using OmniPod insulin infusion pump 5 . History heart disease include coronary artery disease , heart failure , arrhythmias 6 . Cystic fibrosis 7 . Current use oral/inhaled glucocorticoid , betablockers medication , judgment investigator would contraindication participation study . 8 . History ongoing renal disease ( microalbuminuria ) . 9 . Insulin pump user supplement injected intermediate long acting insulin . 10 . Subjects take antidiabetic medication insulin.. 11 . Medical psychiatric condition judgment investigator might interfere completion protocol : 12 . Inpatient psychiatric treatment past 6 month 13 . Uncontrolled adrenal disorder 14 . Abuse alcohol 15 . Pregnancy ( verbal denial pregnancy obtain telephone informed consent , pregnancy test perform camp study device assign ) . 16 . Sexually active female practice acceptable contraceptive method prevent pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Artificial Pancreas Project</keyword>
	<keyword>Diabetes Mellitus , Type 1</keyword>
	<keyword>Insulin pump therapy</keyword>
	<keyword>Continuous Glucose Monitors ( CGM )</keyword>
	<keyword>Juvenile-Onset Diabetes</keyword>
	<keyword>Autoimmune Diabetes</keyword>
	<keyword>Closed-to-Range</keyword>
	<keyword>Diabetes Assistant ( DiAs )</keyword>
</DOC>